| HÁJEK, Roman, Evžen GREGORA, Vladimír MAISNAR, Jiří MINAŘÍK, P. PAVLÍČEK, Luděk POUR, J. RADOCHA, M. SCHÜTZOVÁ, J. STRAUB, Vlastimil ŠČUDLA, Zdeněk ADAM a Petra MÁJKOVÁ. Better treatment response is associated with lenalidomide 25 mg once-daily vs. 25 mg every-other-day in relapsed/refractory multiple myeloma. In 16th Congress of the European Hematology Association. 2011. ISSN 0390-6078. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{943457,
author = {Hájek, Roman and Gregora, Evžen and Maisnar, Vladimír and Minařík, Jiří and Pavlíček, P. and Pour, Luděk and Radocha, J. and Schützová, M. and Straub, J. and Ščudla, Vlastimil and Adam, Zdeněk and Májková, Petra},
booktitle = {16th Congress of the European Hematology Association},
keywords = {multiple myeloma; lenalidomide},
language = {eng},
title = {Better treatment response is associated with lenalidomide 25 mg once-daily vs. 25 mg every-other-day in relapsed/refractory multiple myeloma},
year = {2011}
}
TY - CONF
ID - 943457
AU - Hájek, Roman - Gregora, Evžen - Maisnar, Vladimír - Minařík, Jiří - Pavlíček, P. - Pour, Luděk - Radocha, J. - Schützová, M. - Straub, J. - Ščudla, Vlastimil - Adam, Zdeněk - Májková, Petra
PY - 2011
TI - Better treatment response is associated with lenalidomide 25 mg once-daily vs. 25 mg every-other-day in relapsed/refractory multiple myeloma
KW - multiple myeloma
KW - lenalidomide
N2 - Lenalidomide is active and generally well-tolerated in relapsed/refractory myeloma. These results support the approved 25 mg once-daily dosing of lenalidomide on days 1- 21 of a 28 day cycle in patients with relapsed/refractory multiple myeloma and indicate that every-other-day dosing compromises response with no significant difference in tolerability.
ER -
HÁJEK, Roman, Evžen GREGORA, Vladimír MAISNAR, Jiří MINAŘÍK, P. PAVLÍČEK, Luděk POUR, J. RADOCHA, M. SCHÜTZOVÁ, J. STRAUB, Vlastimil ŠČUDLA, Zdeněk ADAM a Petra MÁJKOVÁ. Better treatment response is associated with lenalidomide 25 mg once-daily vs. 25 mg every-other-day in relapsed/refractory multiple myeloma. In \textit{16th Congress of the European Hematology Association}. 2011. ISSN~0390-6078.
|
